|
1.
|
Varga D, Koenig J, Kuhr K, et al:
Comparison of early onset breast cancer patients to older
premenopausal breast cancer patients. Arch Gynecol Obstet.
Jan;2010.(E-pub ahead of print).
|
|
2.
|
El Saghir NS, Seoud M, Khalil MK, et al:
Effects of young age at presentation on survival in breast cancer.
BMC Cancer. 6:1942006.PubMed/NCBI
|
|
3.
|
Anders CK, Hsu DS, Broadwater G, et al:
Young age at diagnosis correlates with worse prognosis and defines
a subset of breast cancers with shared patterns of gene expression.
J Clin Oncol. 26:3324–3330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bollet MA, Sigal-Zafrani B, Mazeau V, et
al: Age remains the first prognostic factor for loco-regional
breast cancer recurrence in young (<40 years) women treated with
breast conserving surgery first. Radiother Oncol. 82:272–280.
2007.PubMed/NCBI
|
|
5.
|
Wendy Y and Chen MD: MPH. Exogenous and
endogenous hormones and breast cancer. Best Pract Res Clin
Endocrinol Metab. 22:573–585. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Buteau-Lozano H, Ancelin M, Lardeux B,
Milanini J and Perrot-Applanat M: Transcriptional regulation of
vascular endothelial growth factor by estradiol and tamoxifen in
breast cancer cells: a complex interplay between estrogen receptors
alpha and beta. Cancer Res. 62:4977–4984. 2002.
|
|
7.
|
Tai P, Wang J, Jin H, et al: Induction of
regulatory T cells by physiological level estrogen. J Cell Physiol.
214:456–464. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Linderholm BK, Gruvberger-Saal S, Fernö M,
Bendahl PO and Malmström P: Vascular endothelial growth factor is a
strong predictor of early distant recurrences in a prospective
study of premenopausal women with lymph-node negative breast
cancer. Breast. 7:484–491. 2008. View Article : Google Scholar
|
|
9.
|
Xu L, Xu W, Qiu S and Xiong S: Enrichment
of CCR6(+) Foxp3(+) regulatory T cells in the tumor mass correlates
with impaired CD8(+) T cell function and poor prognosis of breast
cancer. Clin Immunol. 135:466–475. 2010.
|
|
10.
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal
therapy for early breast cancer on recurrence and 15-year survival:
an overview of the randomized trials. Lancet. 365:1687–1717.
2005.PubMed/NCBI
|
|
11.
|
Parulekar WR, Day AG, Ottaway JA, et al:
National Cancer Institute of Canada Clinical Trials Group.
Incidence and prognostic impact of amenorrhea during adjuvant
therapy in high-risk premenopausal breast cancer: analysis of a
National Cancer Institute of Canada Clinical Trials Group Study –
NCIC CTG MA5. J Clin Oncol. 23:6002–6008. 2005.PubMed/NCBI
|
|
12.
|
Goel S, Sharma R, Hamilton A and Beith J:
LH-RH agonists for adjuvant therapy of early breast cancer in
premenopausal women. Cochrane Database Syst Rev.
4:CD0045622009.
|
|
13.
|
LH-RH-agonists in Early Breast Cancer
Overview Group; Cuzick J, Ambroisine L, Davidson N, et al: Use of
luteinising-hormone-releasing hormone agonists as adjuvant
treatment in premenopausal patients with hormone-receptor-positive
breast cancer: a meta-analysis of individual patient data from
randomised adjuvant trials. Lancet. 369:1711–1723. 2007. View Article : Google Scholar
|
|
14.
|
Howell A, Cuzick J, Baum M, et al: Results
of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial
after completion of 5 years' adjuvant treatment for breast cancer.
Lancet. 365:60–62. 2005.
|
|
15.
|
Coombes RC, Hall E, Gibson LJ, et al: A
randomized trial of exemestane after two or three years of
tamoxifen therapy in postmenopausal women with primary breast
cancer. N Engl J Med. 350:1081–1092. 2004.PubMed/NCBI
|
|
16.
|
Thürlimann B, Keshaviah A, Coates AS, et
al: A comparison of letrozole and tamoxifen in postmenopausal women
with early breast cancer. N Engl J Med. 353:2747–2757.
2005.PubMed/NCBI
|
|
17.
|
Goss PE, Ingle JN, Martino S, et al:
Randomized trial of letrozole following tamoxifen as extended
adjuvant therapy in receptor-positive breast cancer: updated
findings from NCIC CTG MA. 17. J Natl Cancer Inst. 97:1262–1271.
2005. View Article : Google Scholar
|
|
18.
|
Rossi E, Morabito A, Di Rella F, et al:
Endocrine effects of adjuvant letrozole compared with tamoxifen in
hormone-responsive postmenopausal patients with early breast
cancer: the HOBOE trial. Clin Oncol. 27:3192–3197. 2009. View Article : Google Scholar
|
|
19.
|
Recchia F, Sica G, De Filippis S, Rosselli
M and Rea S: Goserelin as ovarian protection in the adjuvant
treatment of premenopausal breast cancer. A phase II pilot study.
Anticancer Drugs. 13:417–424. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Recchia F, Saggio G, Amiconi G, et al:
Gonadotropin-releasing hormone analogues added to adjuvant
chemotherapy protect ovarian function and improve clinical outcomes
in young women with early breast carcinoma. Cancer. 106:514–523.
2006. View Article : Google Scholar
|
|
21.
|
Recchia F, Saggio G, Cesta A, et al: Phase
II randomized study of interleukin-2 with or without 13-cis
retinoic acid as maintenance therapy in patients with advanced
cancer responsive to chemotherapy. Anticancer Res. 25:3149–3157.
2005.PubMed/NCBI
|
|
22.
|
Recchia F, Accorsi P, Bonfini T, et al:
Randomized trial of sequential administration of G-CSF and GM-CSF
vs. G-CSF alone following peripheral blood progenitor cell
autograft in solid tumors. J Interferon Cytokine Res. 20:171–177.
2000. View Article : Google Scholar
|
|
23.
|
Recchia F, De Fillipis S, Piccinini M and
Rea S: High-dose carboplatin, cyclophosphamide, etoposide with
hematological growth factors, without stem cell support in patients
with advanced cancer. Anticancer Res. 23:4141–4147. 2003.PubMed/NCBI
|
|
24.
|
Simon R: Optimal two-stage designs for
phase II clinical trials. Control Clin Trials. 10:1–10. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Kaplan EL and Meier P: Nonparametric
estimation from incomplete observations. J Am Stat Assoc.
53:457–481. 1958. View Article : Google Scholar
|
|
26.
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors: European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Verheul HM, Hoekman K, Luykx-de Bakker S,
et al: Platelet: transporter of vascular endothelial growth factor.
Clin Cancer Res. 3:2187–2190. 1997.PubMed/NCBI
|
|
28.
|
Bines J, Oleske DM and Cobleigh MA:
Ovarian function in premenopausal women treated with adjuvant
chemotherapy for breast cancer. J Clin Oncol. 5:1718–1729.
1996.PubMed/NCBI
|
|
29.
|
Fraser HM and Duncan WC: SRB Reproduction,
Fertility and Development Award Lecture 2008. Regulation and
manipulation of angiogenesis in the ovary and endometrium. Reprod
Fertil Dev. 21:377–392. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Krüssel J, Behr B, Hirchenhain J, et al:
Expression of vascular endothelial growth factor mRNA in human
preimplantation embryos derived from tripronuclear zygotes. Fertil
Steril. 74:1220–1226. 2000.PubMed/NCBI
|
|
31.
|
Applanat MP, Buteau-Lozano H, Herve MA and
Corpet A: Vascular endothelial growth factor is a target gene for
estrogen receptor and contributes to breast cancer progression. Adv
Exp Med Biol. 617:437–444. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Dabrosin C: Positive correlation between
estradiol and vascular endothelial growth factor but not fibroblast
growth factor-2 in normal human breast tissue in vivo. Clin Cancer
Res. 11:8036–8041. 2005. View Article : Google Scholar
|
|
33.
|
Buteau-Lozano H, Ancelin M, Lardeux B,
Milanini J and Perrot-Applanat M: Transcriptional regulation of
vascular endothelial growth factor by estradiol and tamoxifen in
breast cancer cells: a complex interplay between estrogen receptors
alpha and beta. Cancer Res. 62:4977–4984. 2002.
|
|
34.
|
Gasparini G: Prognostic value of vascular
endothelial growth factor in breast cancer. Oncologist. 5(Suppl 1):
37–44. 2000. View Article : Google Scholar
|
|
35.
|
Prieto GA and Rosenstein Y: Oestradiol
potentiates the suppressive function of human CD4 CD25 regulatory T
cells by promoting their proliferation. Immunology. 118:58–65.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Tai P, Wang J, Jin H, et al: Induction of
regulatory T cells by physiological level estrogen. J Cell Physiol.
214:456–464. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Arruvito L, Sanz M, Banham AH and Fainboim
L: Expansion of CD4+CD25+ and FOXP3+
regulatory T cells during the follicular phase of the menstrual
cycle: implications for human reproduction. J Immunol.
178:2572–2578. 2007.PubMed/NCBI
|
|
38.
|
Gobert M, Treilleux I, Bendriss-Vermare N,
et al: Regulatory T cells recruited through CCL22/CCR4 are
selectively activated in lymphoid infiltrates surrounding primary
breast tumors and lead to an adverse clinical outcome. Cancer Res.
69:2000–2009. 2009. View Article : Google Scholar
|
|
39.
|
Davidson NE, O'Neill AM, Vukov AM, et al:
Chemoendocrine therapy for premenopausal women with axillary lymph
node-positive, steroid hormone receptor-positive breast cancer:
results from INT 0101 (E5188). J Clin Oncol. 23:5973–5882. 2005.
View Article : Google Scholar
|
